- Poster presentation
- Open Access
B cell subsets phenotype in autoimmunity with immunodeficiency: analysis of a cohort of patients with APECED syndrome
© Magnani et al; licensee BioMed Central Ltd. 2011
- Published: 14 September 2011
- Flow Cytometric Analysis
- Effector Memory
- Cell Subset
- Cell Compartment
Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED) is a rare autosomal recessive syndrome due to mutations in AIRE, characterized by autoimmune endocrinopathies and mucocutaneous candidiasis. It is accompanied by serum auto-antibodies whose generation has been mainly related to autoreactive T cells escape from tolerance mechanisms. Recent data suggest a T cell independent mechanism implicated in altered peripheral B cell selection and its possible contribution to the pathogenesis of autoimmune disease. Despite these observations, B cell subsets phenotype in these patients is still poorly characterized.
To perform a detailed analysis of B and T cell subsets in a cohort of APECED patients in order to better understand whether an intrinsic alteration in B cell compartment is present. We also evaluated B lymphocytes related cytokines (BAFF, IL-21) in patients’ sera compared to age matched control.
Flow cytometric analysis of B cell subsets was performed in 12 patients with APECED coming from Sardinia, Italy, compared to age-matched healthy donors. The following B cell subsets were analysed: transitional, naïve, IgM and switched memory and plasmacells; T cell subsets: Treg, CD4 and CD8 T cell subsets (naïve, central memory, effector memory) ELISA assay was performed for cytokines determination in sera.
Analysis show an altered distribution of the immature peripheral B cells compartment in APECED patients and an increased level of BAFF in patients’ sera. The T cell compartment is skewed towards effector memory T cells.
Increasing the knowledge on B cells in APECED patients improves the comprehension of autoimmunity pathogenesis in immunodeficiency and may allow the exploration of the possible clinical efficacy of B cell targeted therapy.
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.